– Rimidi adds Obesity disease view to its platform to preemptively identify and manage cardiometabolic diseases by combining data from multiple sources into disease ‘views’ that provide a holistic overview of a patient.
– With the obesity view, clinicians are better equipped to identify and lower the potential health risks impacting patients
– The addition of obesity to Rimidi’s platform addresses the evolving policies and care around obesity, as the chronic disease requires increased medical attention. Today
Rimidi, an Atlanta-based cloud-based software platform that enables personalized management of chronic cardiometabolic conditions across populations, today announced a new disease ‘view’ within its platform – obesity. The addition of the Obesity review becomes the fifth disease state being managed within the software, along with type 2 diabetes, heart failure, nonalcoholic fatty liver disease and cardiovascular disease.
Obesity Is Recognized As A Chronic Disease
Obesity is now broadly recognized as a chronic disease. Rimidi is aligned with supporting clinicians, patients, and payer in recognizing this disease, optimizing its medical management, reducing cardiovascular risk and supporting self-management efforts.
The addition of obesity to Rimidi’s platform addresses the evolving policies and care around obesity, as the chronic disease requires increased medical attention. Today, obesity affects nearly 40% of Americans and remains one of the biggest contributors to preventable chronic disease and rising US healthcare costs. In fact, this global epidemic is associated with an increased risk of disease and mortality and costs anywhere from $147B to nearly $210B to manage per year.
Rimidi’s Obesity Disease View Features
Rimidi’s platform works within the electronic health record (EHR) to preemptively identify and manage cardiometabolic diseases by combining data from multiple sources into disease ‘views’ that provide a holistic overview of a patient. With the addition of the new obesity view, clinicians can better manage patients based on the latest evidence and guidelines, as well as offer virtual care support, such as remote monitoring and digital health education. In addition to consolidating pertinent information from the EHR that impacts clinical decision making, the new view performs the following:
– Alerts clinicians to risk factors associated with obesity – including hypertension, type 2 diabetes, sleep apnea, PCOS, depression, thyroid disease and nonalcoholic fatty liver disease – and flags whether standard of care for screening and risk-reduction are being met.
– Displays patient’s atherosclerotic-cardiovascular-disease (ASCVD) risk scores so clinicians can easily see patient’s 10-year risk for heart disease or stroke.
– Identifies gaps in prescribing standards, including anti-diabetic and anti-obesity medications, lipid lowering agents, ACE inhibitors, ARBs and aspirin.
“Obesity is a global epidemic in both children and adults, and it’s associated with numerous comorbidities, which manifest differently in each individual patient,” said Lucienne Ide, M.D., Ph.D., founder of Rimidi. “With new innovations in healthcare, however, clinicians are better equipped to combat the obesity epidemic head-on. That’s where Rimidi comes into play. By adding this condition into our existing platform, we can empower physicians with the tools and technology they need to better identify patients who may be at risk.”
